NASDAQ:ZNTL Zentalis Pharmaceuticals Q2 2026 Earnings Results & Report $2.24 -0.08 (-3.45%) Closing price 04:00 PM EasternExtended Trading$2.24 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zentalis Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.59 versus the -$0.49 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET Zentalis Pharmaceuticals EPS ResultsActual EPS-$0.59Consensus EPS -$0.49Beat/MissMissed by -$0.10One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersZentalis Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsZentalis Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zentalis Pharmaceuticals Q2 2026 Earnings FAQ Did Zentalis Pharmaceuticals beat earnings estimates for Q2 2026? Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported earnings of -$0.59 per share for Q2 2026, missing the consensus estimate of -$0.49. The report was announced on Thursday, August 6, 2026. When is Zentalis Pharmaceuticals' next earnings date? Zentalis Pharmaceuticals' next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zentalis Pharmaceuticals on the company's earnings history page. Zentalis Pharmaceuticals Earnings HeadlinesZentalis Pharmaceuticals (NASDAQ:ZNTL) & Aquestive Therapeutics (NASDAQ:AQST) Financial ComparisonOctober 14 at 2:15 AM | americanbankingnews.comZentalis Pharmaceuticals Shares Rise After Leerink UpgradeOctober 6, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8October 5, 2026 | finance.yahoo.comZentalis Pharmaceuticals (ZNTL) Gets a Hold from Wells FargoOctober 5, 2026 | theglobeandmail.comZentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform RatingOctober 5, 2026 | finance.yahoo.comSee More Zentalis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email. Email Address About Zentalis PharmaceuticalsZentalis Pharmaceuticals (NASDAQ:ZNTL) (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies. Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers. WEE1 is a cell-cycle regulator, and the company is studying whether inhibiting the protein can create therapeutic opportunities in tumors with specific genetic or molecular characteristics. Azenosertib remains an investigational therapy and has not been approved for commercial use. The company was established in 2014 and became a publicly traded company in 2020. Zentalis conducts research and clinical development activities in the United States and through clinical trial networks that may include international sites. Its leadership includes Kimberly Blackwell, M.D., who serves as chief executive officer and has experience in oncology drug development and commercialization.View Zentalis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
